PABLO J CAGNONI
CIK 1205703 · President, Global Head of R&D · last filed 2026-06-03
PABLO J CAGNONI is a President, Global Head of R&D who has filed 43 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing shows the insider had shares withheld for taxes covering $2.4M of INCY on Jun 3, 2026. Across all open-market trades the lifetime net is −$7.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $26.5M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$26.51M
7
43
-$7.20M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INCY | President, Global Head of R&D | 240,848 | $108.53 | $26.14M | -$5.44M | 14 | 2026-06-03 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 5 | 2024-06-04 |
| Rubius Therapeutics, Inc. (RUBY) Delisted | CEO and President | 66,082 | $0.08 | $5.5K | $50.6K | 8 | 2023-02-01 |
| CRSP | Director | 7,500 | $49.80 | $373.5K | -$1.73M | 6 | 2019-11-21 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | — | — | — | $0 | 2 | 2017-06-02 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | EVP, Global R&D and Tech Ops | 16,257 | — | — | $0 | 1 | 2013-03-13 |
| ALLOS THERAPEUTICS INC (ALTH) Delisted | Sr. VP, Chief Medical Officer | 25,200 | — | — | -$73.3K | 6 | 2009-10-02 |
Recent Filings
43 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-03 | INCY | Tax (F) | −25,469 | -$2.43M | EDGAR |
| 2026-05-20 | INCY | Grant (A) | +31,517 | $0 | EDGAR |
| 2026-04-21 | INCY | Mixed | — | -$505.3K | EDGAR |
| 2026-04-17 | INCY | Grant (A) | +27,892 | $0 | EDGAR |
| 2026-03-19 | INCY | Mixed | — | -$581.8K | EDGAR |
| 2026-02-23 | INCY | Mixed | — | -$734.1K | EDGAR |
| 2026-01-21 | INCY | Grant (A) | — | $0 | EDGAR |
| 2025-07-16 | INCY | Mixed | +13,630 | -$268.9K | EDGAR |
| 2025-01-22 | INCY | Grant (A) | — | $0 | EDGAR |
| 2024-07-17 | INCY | Mixed | +19,102 | -$48.1K | EDGAR |